The addition of these new ER-negative loci may improve overall risk prediction models for ER-negative disease in the general population and for breast cancer among BRCA1 mutation carriers by enhancing the contribution of current polygenic risk prediction models21, 22. This evidence concerns the gene BRCA1 and breast carcinoma.